Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PENETRATION OF 3'-AMINO-3'-DEOXYTHYMIDINE, A CYTOTOXIC METABOLITE OF ZIDOVUDINE, INTO THE CEREBROSPINAL-FLUID OF HIV-1-INFECTED PATIENTS
Autore:
HOETELMANS RMW; KRAAIJEVELD CL; MEENHORST PL; MULDER JW; BURGER DM; KOKS CHW; BEIJNEN JH;
Indirizzi:
SLOTERVAART HOSP,DEPT PHARM,LOUWESWEG 6 NL-1066 EC AMSTERDAM NETHERLANDS SLOTERVAART HOSP,DEPT NEUROL NL-1066 EC AMSTERDAM NETHERLANDS SLOTERVAART HOSP,DEPT INTERNAL MED NL-1066 EC AMSTERDAM NETHERLANDS UNIV NIJMEGEN HOSP,DEPT CLIN PHARM NL-6500 HB NIJMEGEN NETHERLANDS
Titolo Testata:
Journal of acquired immune deficiency syndromes and human retrovirology
fascicolo: 2, volume: 15, anno: 1997,
pagine: 131 - 136
SICI:
1077-9450(1997)15:2<131:PO3ACM>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
AIDS DEMENTIA COMPLEX; PERFORMANCE LIQUID-CHROMATOGRAPHY; HUMAN LIVER-MICROSOMES; 3'-AZIDO-3'-DEOXYTHYMIDINE ZIDOVUDINE; TOXIC CATABOLITE; HUMAN PLASMA; IN-VITRO; HIV; PHARMACOKINETICS; PATHOGENESIS;
Keywords:
3'-AMINO-3'-DEOXYTHYMIDINE (AMT); CEREBROSPINAL FLUID (CSF); HIV INFECTION, ZIDOVUDINE (ZDV);
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
25
Recensione:
Indirizzi per estratti:
Citazione:
R.M.W. Hoetelmans et al., "PENETRATION OF 3'-AMINO-3'-DEOXYTHYMIDINE, A CYTOTOXIC METABOLITE OF ZIDOVUDINE, INTO THE CEREBROSPINAL-FLUID OF HIV-1-INFECTED PATIENTS", Journal of acquired immune deficiency syndromes and human retrovirology, 15(2), 1997, pp. 131-136

Abstract

The penetration of 3'-amino-3'-deoxythymidine (AMT) into the cerebrospinal fluid (CSF) of HIV-1-infected patients has been investigated. In23 patients who used zidovudine (ZDV) chronically, CSF and plasma samples were assayed for AMT and ZDV. The influences of time between ZDV oral administration and lumbar puncture, of ZDV dose, and of the medical indication for lumbar puncture based on the concentration of AMT inCSF and on the CSF-plasma concentration ratio were investigated. AMT can be detected in the CSF after oral administration of ZDV; concentrations of AMT in CSF ranged from 0.75 to 4.8 ng/ml (median, 1.7 ng/ml). The median CSF-plasma concentration ratio was 1, and equaled that forZDV. CSF and plasma concentrations of AMT were approximately threefold higher in patients with cerebral toxoplasmosis; the CSF-plasma concentration ratio remained equal to unity in these cases. This phenomenonmight be caused by a pharmacokinetic interaction between AMT and pyrimethamine, sulfadiazine, folinic acid, or a combination of these. The clinical relevance of AMT, especially the possibility of decreased efficacy of ZDV, throughout the body and in the central nervous system, and the involvement of this metabolite in ZDV-induced myelosuppression,remains to be established.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 06:24:21